A multivalent T-antigen-based vaccine for Group A Streptococcus.

Show simple item record

dc.contributor.author Loh, Jacelyn MS
dc.contributor.author Rivera-Hernandez, Tania
dc.contributor.author McGregor, Reuben
dc.contributor.author Khemlani, Adrina Hema J
dc.contributor.author Tay, Mei Lin
dc.contributor.author Cork, Amanda J
dc.contributor.author M Raynes, Jeremy
dc.contributor.author Moreland, Nicole J
dc.contributor.author Walker, Mark J
dc.contributor.author Proft, Thomas
dc.coverage.spatial England
dc.date.accessioned 2021-07-15T21:41:03Z
dc.date.available 2021-07-15T21:41:03Z
dc.date.issued 2021-2-23
dc.identifier.citation Scientific reports 11(1):4353 23 Feb 2021
dc.identifier.issn 2045-2322
dc.identifier.uri https://hdl.handle.net/2292/55576
dc.description.abstract Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation of the host during infection. The major protein component of the GAS pilus is the T-antigen, which multimerises to form the pilus shaft. There are currently no licenced vaccines against GAS infections and the T-antigen represents an attractive target for vaccination. We have generated a multivalent vaccine called TeeVax1, a recombinant protein that consists of a fusion of six T-antigen domains. Vaccination with TeeVax1 produces opsonophagocytic antibodies in rabbits and confers protective efficacy in mice against invasive disease. Two further recombinant proteins, TeeVax2 and TeeVax3 were constructed to cover 12 additional T-antigens. Combining TeeVax1-3 produced a robust antibody response in rabbits that was cross-reactive to a full panel of 21 T-antigens, expected to provide over 95% vaccine coverage. These results demonstrate the potential for a T-antigen-based vaccine to prevent GAS infections.
dc.format.medium Electronic
dc.language eng
dc.publisher Springer Science and Business Media LLC
dc.relation.ispartofseries Scientific reports
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject Science & Technology
dc.subject Multidisciplinary Sciences
dc.subject Science & Technology - Other Topics
dc.subject CELL-ADHESION
dc.subject NEW-ZEALAND
dc.subject PYOGENES
dc.subject SAFETY
dc.subject PILI
dc.title A multivalent T-antigen-based vaccine for Group A Streptococcus.
dc.type Journal Article
dc.identifier.doi 10.1038/s41598-021-83673-4
pubs.issue 1
pubs.begin-page 4353
pubs.volume 11
dc.date.updated 2021-06-09T03:39:02Z
dc.rights.holder Copyright: The authors en
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/33623073
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype research-article
pubs.subtype Journal Article
pubs.elements-id 842001
dc.identifier.eissn 2045-2322
dc.identifier.pii 10.1038/s41598-021-83673-4
pubs.number 4353
pubs.online-publication-date 2021-2-23

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace